• KOL
    • Essential Thrombocythemia
    • Maria Luigia Randi
    • Maria Luigia Randi: Influence Statistics

      Maria Luigia Randi

      Maria Luigia Randi

      First Clinical Medicine, Department of Medicine – DIMED, University of Padua, Italy | Department of Medicine-DIMED, University of Padua, Via Giustiniani 2, 35128, Padua, Italy ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Maria Luigia Randi:Expert Impact

      Concepts for whichMaria Luigia Randihas direct influence:Essential thrombocythemia,Polycythemia vera,Pregnancy complications,Large cohort,Acute leukemia,Fxii deficiency,Thrombotic events,Venous thrombosis.

      Maria Luigia Randi:KOL impact

      Concepts related to the work of other authors for whichfor which Maria Luigia Randi has influence:Essential thrombocythemia,Polycythemia vera,Myeloproliferative neoplasms,Janus kinase,Primary myelofibrosis,Platelet count,Patients pv.

      KOL Resume for Maria Luigia Randi

      Year
      2021

      First Clinical Medicine, Department of Medicine – DIMED, University of Padua, Italy

      2020

      First Clinical Medicine, Department of Internal Medicine-DIMED, University of Padua, via Giustiniani 2, 35123 Padova, Italy.

      Department of Medicine (DIMED), University of Padova, Padua, Italy;

      2019

      University of Padua Medical School, Department of Medicine, Padua, Italy.

      2018

      First Medical Clinic, Department of Medicine‐DIMED, University of Padova, Padova, Italy

      2017

      Department of Medicine, DIMED‐ University of Padua, Padua, Italy

      2016

      Internal Medicine Dept., DIMED, University Hospital, Padova, Italy

      2015

      Division of Hematology University of Padua Padua Italy

      2014

      University of Padua Department of Medicine ‐DIMED Padua Italy

      2013

      University of Padua Medical School Department of Medicine‐DIMED Padua Italy

      2012

      Department of Internal Medicine, University of Padua, Padua Italy

      2011

      From the Ospedali Riuniti di Bergamo, Bergamo

      University of Florence, Florence, Italy

      and Mayo Clinic, Rochester, MN.

      S. Bortolo Hospital, Vicenza

      2010

      Department of Medical and Surgical Sciences, Internal Medicine, University of Padua Medical School, Padua, Italy

      2009

      Department of Medical and Surgical Sciences, University of Padua Medical School, Italy

      2008

      Department of Medical and Surgical Sciences and

      University Unit, Padova, Italy

      2007

      Dipartimento di Scienze Medico-Chirurgiche, Sezione Medicina Interna, Università di Padova, Padova;

      2006

      Internal Medicine, Department of Medical and Surgical Sciences, University of Padova, Padova, Italy

      2005

      Internal Medicine, Department of Medical and Surgical Sciences, University of Padua Medical School, Padua,

      2004

      From the Consorzio Mario Negri Sud, Santa Maria Imbaro; Policlinico S Orsola, Bologna; Ospedale S Gerardo, Monza; University of Padua, Dip. Scienze Mediche e Chirurgiche, Padova; Ospedale Umberto I, Venezia-Mestre; Catholic University School of Medicine, Rome; Ospedali Riuniti, Bergamo; Ospedale di Reggio Emilia; Ospedale S Giovanni e Paolo, Venezia; University of Rome “La Sapienza,” Italy; Sahlgrenska Hospital, Göteborg, Sweden; Department of Hematology and Blood Coagulation, University of Vienna, Austria; Tel-Aviv Souraski Medical Center, Israel; and Hospital Universitario S Carlos, Madrid, Spain

      Reprints: Fabrizio Fabris, Department of Medical and Surgical Sciences, via Ospedale 105, 35128 Padova, Italy; e-mail: fabrizio.fabris{at}unipd.it.

      University of Padua Medical School, Department of Medical and Surgical Sciences, Padua, Italy

      2003

      Department of Medical and Surgical Sciences, II Chair of Internal Medicine, University of Padua Medical School, via Ospedale 105, 35128, Padua, Italy

      2002

      From the Clinica Medica II, Department of Medical and Surgical Sciences, University of Padua Medical School, Padova, Italy

      2001

      Department of Medical and Surgical Sciences, University of Padua Medical School and

      2000

      Department of Medical and Surgical Science, II Chair of Internal Medicine

      Transfusion Center, Padua City Hospital, Padua, Italy

      1999

      From the Department of Medical and Surgical Sciences, II Chair of Internal Medicine; and

      Institute of Medical Semeiotics, Chair of Internal Medicine

      1998

      From the Institute of Medical Semeiotics, II Chair of Internal Medicine, University of Padua Medical School, Padua, Italy

      1997

      Institute of Medical Semiotics, Second Chair of Internal Medicine and of Clinical Methodology, University of Padua Medical School, Padua, Italy

      1996

      Institute of Medical Semeiotics, Chairs of Semeiotic and Internal Medicine, University of Padua Medical School, Padua, Italy

      1995

      Institute of Medical Semeiotic, Fourth Chair of Internal Medicine, University of Padua Medical School, Padua, Italy

      1994

      Institute of Medical Semeiotics, Padua Medical School, Italy.

      1993

      Institute of Medical Semeiotics, Padua University School of Medicine, Padova, Italy.

      1992

      Universita'degli Studi di Padova, Istituto di Semeiotica Medica, 35100 Padova, Italy

      1991

      Institute of Medical Semeiotics, Second Chair of Medicine, University of Padua Medical School, Padua, Italy

      1990

      University of Padua Medical School, Institute of Medical Semeiotics, Second Chair of Medicine, Padua, Italy.

      1989

      University of Padua Medical School, Institute of Medical Semeiotics and Second Chair of Medicine, Padova, Italy

      1988

      Institute of Medical Semeiotics, Second Chair of Medicine, University of Padua Medical School, Italy.

      1987

      Padua

      1985

      University of Padua Medical School, Institute of Medical Semeiotics, Second Chair of Medicine and Blood Bank Transfusion Center, Padua, Italy

      1984

      Institute of Medical Semeiotics, Second Chair of Medicine, University of Padua Medical School, Padua;, Central Laboratory, Padua City Hospital, Padua, Italy

      1983

      Institute of Medical Semiotics and Second Chair of Medicine, University of Padua Medical School, Padua, Italy

      Istituto di Semeiotica Medica, Università degli Studi di Padova, Via Ospedale Civile 105, 35100, Padova, Italia

      Sample of concepts for which Maria Luigia Randi is among the top experts in the world.
      Concept World rank
      leukemialymphoma thrombosis leukemia #1
      children haematologic malignacies #1
      erythrocytosis reveals #1
      jak2v617f mutation patient #1
      mutation pedigree polycythemia #1
      clinical histological picture #1
      mpl codon 38 #1
      studies thrombocytosis #1
      heterozygous v617fjak2 children #1
      paediatric watchandwait strategy #1
      mpl codon #1
      thrombocythemia rare #1
      children negative cases #1
      child essential #1
      thromboses hemorrhages #1
      transversion mpl codon #1
      major thrombotic complication #1
      thrombocytosis diagnostic #1
      thrombocythemia young #1
      essential adolescent #1
      thrombocythemia thrombosis #1
      children clonality #1
      haemorrhages diagnosis #1
      thrombocythemia background #1
      anecdotal experiences regard #1
      male rna thrombocythemia #1
      v617fjak2 negative #1
      adults thrombosis #1
      male thrombocythemia #1
      children essential thrombocythemia #1
      common complication low #1
      thrombocythemia 20 #1
      thrombosis young patients #1
      children thrombopoietin thrombocythemia #1
      thrombocythemia child #1
      heterozygous v617fjak2 #1
      hematocrit pv #1
      pv diagnosed #1
      adult patients mutation #1
      busulfan female humans #1
      studies thrombocythemia #1
      molecular abnormality 40 #1
      platelets v617fjak2 #1
      ipsett #1
      51 pv #1
      ifns firstline #1
      rna thrombocythemia #1
      thrombocythemia essential thrombosis #1

      Prominent publications by Maria Luigia Randi

      KOL-Index: 10996

      PURPOSE: The WHO diagnostic criteria underscore the role of bone marrow (BM) morphology in distinguishing essential thrombocythemia (ET) from early/prefibrotic primary myelofibrosis (PMF). This study examined the clinical relevance of such a distinction.

      METHODS: Representatives from seven international centers of excellence for myeloproliferative neoplasms convened to create a clinicopathologic database of patients previously diagnosed as having ET (N = 1,104). Study eligibility ...

      Known for Essential Thrombocythemia | Early Prefibrotic Pmf | 15 Years | International Study | 1 Year Diagnosis
      KOL-Index: 9667

      Essential thrombocythemia (ET) may occur in women of childbearing age. To investigate the risk of pregnancy complications, we studied 103 pregnancies that occurred in 62 women with ET. The 2-tailed Fisher exact test showed that pregnancy outcome was independent from that of a previous pregnancy. The rate of live birth was 64%, and 51% of pregnancies were uneventful. Maternal complications occurred in 9%, while fetal complications occurred in 40% of pregnancies. The Mantel-Haenszel method ...

      Known for Pregnancy Complications | Fetal Loss | Platelet Count | Patients Essential Thrombocythemia | Live Birth
      KOL-Index: 8954

      By means of immunoblotting and monoclonal antibody immobilization of platelet antigens (MAIPA) we have studied the specificity of antiplatelet antibodies in patients with antiphospholipid antibodies and thrombocytopenia defined as presence of anticardiolipin IgG and a platelet count below 100 x 10(9)/l. The study group consisted of 10 patients with systemic lupus erythematosus (SLE), 8 patients with primary anti-phospholipid syndrome (PAPS) and 16 patients with idiopathic ...

      Known for Patients Antiphospholipid Antibodies | Platelet Antigens | Chronic Itp | Antiphospholipid Syndrome | Thrombocytopenic Purpura
      KOL-Index: 8900

      Accurate prediction of thrombosis in essential thrombocythemia (ET) provides the platform for prospective studies exploring preventive measures. Current risk stratification for thrombosis in ET is 2-tiered and considers low- and high-risk categories based on the respective absence or presence of either age > 60 years or history of thrombosis. In an international study of 891 patients with World Health Organization (WHO)-defined ET, we identified additional independent risk factors ...

      Known for Health Organization | Essential Thrombocythemia | International Prognostic | Thrombosis Risk | 1 Point
      KOL-Index: 8531

      JAK2 617V>F mutation occurs in a homozygous state in 25% to 30% of patients with polycythemia vera (PV) and 2% to 4% with essential thrombocythemia (ET). Whether homozygosity associates with distinct clinical phenotypes is still under debate. This retrospective multicenter study considered 118 JAK2 617V>F homozygous patients (104 PV, 14 ET) whose clinical characteristics were compared with those of 587 heterozygous and 257 wild-type patients. Irrespective of their clinical diagnosis, ...

      Known for Homozygous Jak2 | Essential Thrombocythemia | Polycythemia Vera | Leukocyte Count | Thrombosis Risk Pv
      KOL-Index: 8137

      To investigate the characteristics and clinical course of cerebral vein thrombosis (CVT) in patients with myeloproliferative neoplasms (MPN) we compared 48 patients with MPN and CVT (group MPN-CVT) to 87 with MPN and other venous thrombosis (group MPN-VT) and 178 with MPN and no thrombosis (group MPN-NoT) matched by sex, age at diagnosis of MPN (±5 years) and type of MPN. The study population was identified among 5,500 patients with MPN, from January 1982 to June 2013. Thrombophilia ...

      Known for Myeloproliferative Neoplasms | Cerebral Vein Thrombosis | Cvt Patients | Essential Thrombocythemia | Mpn Venous
      KOL-Index: 7895

      In an international collaborative study, a central histologic review identified 891 patients with essential thrombocythemia, strictly defined by World Health Organization criteria. After a median follow-up of 6.2 years, 109 (12%) patients experienced arterial (n = 79) or venous (n = 37) thrombosis. In multivariable analysis, predictors of arterial thrombosis included age more than 60 years (P = .03; hazard ratio [HR] = 1.7), thrombosis history (P = .003; HR = 2.1), cardiovascular risk ...

      Known for Venous Thrombosis | International Study | 891 Patients | Janus Kinase | Defined Essential
      KOL-Index: 7718

      Polycythemia vera (PV) is currently diagnosed by the World Health Organization (WHO) criteria regarding hemoglobin (HB) levels and JAK2V617F and related mutations or by the British Committee for Standards in Haematology (BCSH) guidelines predominantly based on hematocrit (HCT) values (>52% in men and >48% in women) in JAK2 mutated patients. We examined clinical features at diagnosis and outcome in 397 mutated PV patients showing a bone marrow (BM) morphology conforming with the WHO ...

      Known for Polycythemia Vera | Mpv Patients | Bone Marrow | Overt Pv | Janus Kinase
      KOL-Index: 7556

      Under the auspices of an International Working Group, seven centers submitted diagnostic and follow-up information on 1545 patients with World Health Organization-defined polycythemia vera (PV). At diagnosis, median age was 61 years (51% females); thrombocytosis and venous thrombosis were more frequent in women and arterial thrombosis and abnormal karyotype in men. Considering patients from the center with the most mature follow-up information (n=337 with 44% of patients followed to ...

      Known for International Study | Abnormal Karyotype | 1545 Patients | Leukemic Transformation | Venous Thrombosis
      KOL-Index: 7125

      The presence and specificity of antiplatelet autoantibodies in 32 patients with primary and 18 patients with secondary autoimmune thrombocytopenic purpura (AITP), as well as 11 nonthrombocytopenic patients with systemic autoimmune diseases, were studied. By means of the direct and indirect monoclonal antibody immobilization of platelet antigen (MAIPA) assay, antiplatelet autoantibodies were detected using monoclonal antibodies specific for platelet glycoproteins (GPs) Ib, IIb/IIIa, ...

      Known for Autoimmune Diseases | Patients Thrombocytopenia | Gps Iib Iiia | Platelet Glycoproteins | Primary Aitp
      KOL-Index: 6993

      We examined the baseline features and clinical outcomes of 140 patients presenting with JAK2V617F positivity and a bone marrow morphology conforming with WHO criteria of polycythemia vera (PV), but a hemoglobin level of <18.5 g/dL in males (range 16.0-18.4) and <16.5 g/dL in females (range 15.0-16.4). This cohort operationally referred to as masked PV (mPV) was compared with 257 patients with overt PV and displayed male predominance, a more frequent history of arterial thrombosis and ...

      Known for Polycythemia Vera | Janus Kinase | Pv Mpv | Acute Leukemia | Arterial Thrombosis
      KOL-Index: 6990

      BACKGROUND: As reported by major clinical series in the literature, about 2% of patients receiving unfractionated heparin (UFH) develop immune-mediated (type II) heparin-induced thrombocytopenia (HIT) that may be complicated in 30-75% of cases by a paradoxical thrombotic syndrome (HITTS), either arterial or venous. HITTS carries relevant rates of mortality and morbidity, amongst which cerebral and/or myocardial infarction and limb amputations. It is unclear as yet why some patients ...

      Known for Arterial Thrombosis | Hit Patients | Antibodies Anticoagulants | Immune Mediated | Unfractionated Heparin

      Key People For Essential Thrombocythemia

      Top KOLs in the world
      #1
      Tefferi Tefferi
      essential thrombocythemia primary myelofibrosis polycythemia vera
      #2
      Tiziano Barbui
      polycythemia vera essential thrombocythemia myeloproliferative neoplasms
      #3
      Guido Finazzi
      polycythemia vera essential thrombocythemia myeloproliferative neoplasms
      #4
      Alessandro Maria Vannucchi
      speakers bureau board directors polycythemia vera
      #5
      Claire N Harrison
      speakers bureau board directors advisory committees
      #6
      Francesco Passamonti
      speakers bureau polycythemia vera board directors

      First Clinical Medicine, Department of Medicine – DIMED, University of Padua, Italy | Department of Medicine-DIMED, University of Padua, Via Giustiniani 2, 35128, Padua, Italy | First Medical Clinic, Department of Medicine—DIMED, University of Padua,

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.